Trade FibroGen, Inc - FGEN CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
Spread | 0.05 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 50% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
FibroGen Inc ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Prev. Close* | 2.55 |
Open* | 2.49 |
1-Year Change* | -86.66% |
Day's Range* | 2.31 - 2.51 |
52 wk Range | 0.33-25.69 |
Average Volume (10 days) | 1.11M |
Average Volume (3 months) | 35.86M |
Market Cap | 78.16M |
P/E Ratio | -100.00K |
Shares Outstanding | 98.34M |
Revenue | 154.98M |
EPS | -3.06 |
Dividend (Yield %) | N/A |
Beta | 0.67 |
Next Earnings Date | Feb 26, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Mar 28, 2024 | 2.32 | -0.20 | -7.94% | 2.52 | 2.56 | 2.29 |
Mar 27, 2024 | 2.55 | 0.15 | 6.25% | 2.40 | 2.65 | 2.29 |
Mar 26, 2024 | 2.42 | -0.20 | -7.63% | 2.62 | 2.76 | 2.39 |
Mar 25, 2024 | 2.62 | 0.07 | 2.75% | 2.55 | 2.76 | 2.51 |
Mar 22, 2024 | 2.56 | 0.17 | 7.11% | 2.39 | 2.64 | 2.34 |
Mar 21, 2024 | 2.41 | 0.10 | 4.33% | 2.31 | 2.46 | 2.29 |
Mar 20, 2024 | 2.33 | 0.10 | 4.48% | 2.23 | 2.37 | 2.13 |
Mar 19, 2024 | 2.33 | 0.10 | 4.48% | 2.23 | 2.37 | 2.11 |
Mar 18, 2024 | 2.15 | 0.06 | 2.87% | 2.09 | 2.35 | 1.93 |
Mar 15, 2024 | 2.07 | 0.06 | 2.99% | 2.01 | 2.18 | 1.99 |
Mar 14, 2024 | 2.08 | 0.10 | 5.05% | 1.98 | 2.14 | 1.90 |
Mar 13, 2024 | 1.99 | 0.13 | 6.99% | 1.86 | 2.15 | 1.83 |
Mar 12, 2024 | 1.87 | 0.15 | 8.72% | 1.72 | 2.04 | 1.72 |
Mar 11, 2024 | 1.68 | -0.03 | -1.75% | 1.71 | 1.81 | 1.67 |
Mar 8, 2024 | 1.78 | 0.00 | 0.00% | 1.78 | 1.86 | 1.73 |
Mar 7, 2024 | 1.77 | -0.04 | -2.21% | 1.81 | 1.88 | 1.69 |
Mar 6, 2024 | 1.84 | -0.03 | -1.60% | 1.87 | 1.93 | 1.82 |
Mar 5, 2024 | 1.91 | 0.05 | 2.69% | 1.86 | 1.94 | 1.76 |
Mar 4, 2024 | 1.95 | 0.16 | 8.94% | 1.79 | 1.99 | 1.75 |
Mar 1, 2024 | 1.80 | 0.06 | 3.45% | 1.74 | 1.87 | 1.67 |
FibroGen, Inc Events
Time (UTC) | Country | Event |
---|---|---|
Monday, May 6, 2024 | ||
Time (UTC) 10:59 | Country US
| Event Q1 2024 FibroGen Inc Earnings Release Q1 2024 FibroGen Inc Earnings ReleaseForecast -Previous - |
Thursday, June 6, 2024 | ||
Time (UTC) 15:00 | Country US
| Event FibroGen Inc Annual Shareholders Meeting FibroGen Inc Annual Shareholders MeetingForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 140.734 | 235.309 | 176.319 | 256.577 | 212.958 |
Revenue | 140.734 | 235.309 | 176.319 | 256.577 | 212.958 |
Total Operating Expense | 441.759 | 523.839 | 368.199 | 345.891 | 299.651 |
Selling/General/Admin. Expenses, Total | 127.474 | 120.557 | 97.238 | 126.557 | 63.812 |
Research & Development | 296.791 | 387.043 | 252.924 | 209.265 | 235.839 |
Operating Income | -301.025 | -288.53 | -191.88 | -89.314 | -86.693 |
Interest Income (Expense), Net Non-Operating | 6.156 | -2.153 | 3.151 | 12.672 | 0.577 |
Net Income Before Taxes | -294.869 | -290.683 | -188.729 | -76.642 | -86.116 |
Net Income After Taxes | -295.227 | -291.03 | -189.089 | -76.97 | -86.42 |
Net Income Before Extra. Items | -293.654 | -290.023 | -189.291 | -76.97 | -86.42 |
Net Income | -293.654 | -290.023 | -189.291 | -76.97 | -86.42 |
Income Available to Common Excl. Extra. Items | -293.654 | -290.023 | -189.291 | -76.97 | -86.42 |
Income Available to Common Incl. Extra. Items | -293.654 | -290.023 | -189.291 | -76.97 | -86.42 |
Diluted Net Income | -293.654 | -290.023 | -189.291 | -76.97 | -86.42 |
Diluted Weighted Average Shares | 93.582 | 92.349 | 89.854 | 86.633 | 84.062 |
Diluted EPS Excluding Extraordinary Items | -3.13793 | -3.14051 | -2.10665 | -0.88846 | -1.02805 |
Diluted Normalized EPS | -3.13793 | -3.14051 | -2.10665 | -0.88846 | -1.02805 |
Total Extraordinary Items | |||||
Cost of Revenue, Total | 20.28 | 12.871 | 8.869 | 1.147 | |
Gross Profit | 120.454 | 222.438 | 167.45 | 255.43 | |
Depreciation / Amortization | 0.587 | 4.639 | 10.369 | 10.307 | |
Other Operating Expenses, Total | -3.373 | -1.271 | -1.201 | -1.385 | |
Equity In Affiliates | 1.573 | 1.007 | -0.202 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 44.319 | 36.161 | 34.367 | 15.735 | 29.806 |
Revenue | 44.319 | 36.161 | 34.367 | 15.735 | 29.806 |
Cost of Revenue, Total | 5.708 | 3.491 | 4.925 | 4.308 | 6.809 |
Gross Profit | 38.611 | 32.67 | 29.442 | 11.427 | 22.997 |
Total Operating Expense | 132.367 | 112.252 | 100.519 | 109.392 | 108.03 |
Selling/General/Admin. Expenses, Total | 31.181 | 34.275 | 33.966 | 29.902 | 30.258 |
Research & Development | 95.478 | 74.486 | 61.628 | 75.182 | 70.963 |
Other Operating Expenses, Total | |||||
Operating Income | -88.048 | -76.091 | -66.152 | -93.657 | -78.224 |
Interest Income (Expense), Net Non-Operating | -0.417 | -1.336 | -0.195 | 1.714 | 5.058 |
Net Income Before Taxes | -88.465 | -77.427 | -66.347 | -91.943 | -73.166 |
Net Income After Taxes | -88.23 | -77.501 | -66.455 | -92.057 | -73.189 |
Equity In Affiliates | 0.55 | 0.796 | 0.28 | 0.407 | 0.565 |
Net Income Before Extra. Items | -87.68 | -76.705 | -66.175 | -91.65 | -72.624 |
Net Income | -87.68 | -76.705 | -66.175 | -91.65 | -72.624 |
Income Available to Common Excl. Extra. Items | -87.68 | -76.705 | -66.175 | -91.65 | -72.624 |
Income Available to Common Incl. Extra. Items | -87.68 | -76.705 | -66.175 | -91.65 | -72.624 |
Diluted Net Income | -87.68 | -76.705 | -66.175 | -91.65 | -72.624 |
Diluted Weighted Average Shares | 97.729 | 94.691 | 94.035 | 93.767 | 93.475 |
Diluted EPS Excluding Extraordinary Items | -0.89717 | -0.81006 | -0.70373 | -0.97742 | -0.77694 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.89717 | -0.81006 | -0.70373 | -0.97742 | -0.77694 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 492.826 | 474.059 | 755.11 | 702.49 | 690.015 |
Cash and Short Term Investments | 422.008 | 405.19 | 686.537 | 533.757 | 621.402 |
Cash | 135.819 | 111.422 | 88.046 | 40.715 | 38.783 |
Cash & Equivalents | 19.881 | 59.801 | 590.347 | 85.551 | 50.475 |
Short Term Investments | 266.308 | 233.967 | 8.144 | 407.491 | 532.144 |
Total Receivables, Net | 16.299 | 25.401 | 41.883 | 153.665 | 63.684 |
Accounts Receivable - Trade, Net | 28.387 | 36.331 | 46.01 | 158.51 | 16.474 |
Prepaid Expenses | 9.73 | 7.383 | 8.353 | 6.464 | 4.929 |
Total Assets | 610.087 | 773.821 | 826.84 | 857.397 | 880.598 |
Property/Plant/Equipment, Total - Net | 100.933 | 120.15 | 65.296 | 84.276 | 127.198 |
Property/Plant/Equipment, Total - Gross | 253.644 | 252.362 | 199.305 | 195.752 | 192.397 |
Accumulated Depreciation, Total | -152.711 | -132.212 | -134.009 | -111.476 | -65.199 |
Long Term Investments | 9.409 | 171.621 | 2.972 | 61.118 | 55.82 |
Other Long Term Assets, Total | 6.919 | 7.991 | 3.462 | 9.513 | 7.565 |
Total Current Liabilities | 273.562 | 225.497 | 163.187 | 102.745 | 89.033 |
Accounts Payable | 30.758 | 26.097 | 24.789 | 6.088 | 9.139 |
Accrued Expenses | 229.639 | 180.356 | 104.384 | 83.816 | 66.123 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 13.129 | 19.033 | 21.684 | 0.49 | 13.771 |
Total Liabilities | 631.534 | 564.675 | 404.662 | 341.262 | 371.399 |
Total Long Term Debt | 17.054 | 17.616 | 44.088 | 55.531 | 113.955 |
Long Term Debt | 16.917 | 17.613 | 18.697 | 16.78 | 16.798 |
Capital Lease Obligations | 0.137 | 0.003 | 25.391 | 38.751 | 97.157 |
Minority Interest | 19.967 | 19.967 | 19.271 | 19.271 | 19.271 |
Other Liabilities, Total | 320.951 | 292.403 | 169.441 | 163.715 | 149.14 |
Total Equity | -21.447 | 209.146 | 422.178 | 516.135 | 509.199 |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.942 | 0.929 | 0.914 | 0.877 | 0.854 |
Additional Paid-In Capital | 1541.02 | 1476.41 | 1399.77 | 1300.72 | 1226.45 |
Retained Earnings (Accumulated Deficit) | -1557.69 | -1264.03 | -974.011 | -784.72 | -715.827 |
Other Equity, Total | -5.72 | -4.163 | -4.499 | -0.747 | -2.281 |
Total Liabilities & Shareholders’ Equity | 610.087 | 773.821 | 826.84 | 857.397 | 880.598 |
Total Common Shares Outstanding | 94.1661 | 92.881 | 91.441 | 87.657 | 85.432 |
Total Inventory | 40.436 | 31.015 | 16.53 | 6.887 | |
Other Current Assets, Total | 4.353 | 5.07 | 1.807 | 1.717 | |
Current Port. of LT Debt/Capital Leases | 0.036 | 0.011 | 12.33 | 12.351 | |
Deferred Income Tax | 9.192 | 8.675 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 364.108 | 411.357 | 430.549 | 492.826 | 474.224 |
Cash and Short Term Investments | 251.34 | 335.716 | 355.949 | 422.008 | 408.52 |
Cash | 70.982 | 81.727 | 145.81 | 135.819 | 104.509 |
Cash & Equivalents | 49.932 | 70.858 | 42.74 | 19.881 | 51.451 |
Short Term Investments | 130.426 | 183.131 | 167.399 | 266.308 | 252.56 |
Total Receivables, Net | 31.694 | 25.599 | 17.654 | 16.299 | 15.328 |
Accounts Receivable - Trade, Net | 54.61 | 45.55 | 29.217 | 28.387 | 29.665 |
Total Inventory | 40.696 | 41.179 | 42.456 | 40.436 | 39.95 |
Prepaid Expenses | 40.378 | 8.863 | 14.49 | 9.73 | 10.426 |
Other Current Assets, Total | 4.353 | ||||
Total Assets | 460.426 | 515.127 | 538.544 | 610.087 | 608.837 |
Property/Plant/Equipment, Total - Net | 85.76 | 91.233 | 95.367 | 100.933 | 105.19 |
Property/Plant/Equipment, Total - Gross | 253.644 | ||||
Accumulated Depreciation, Total | -152.711 | ||||
Long Term Investments | 4.534 | 6.112 | 5.884 | 9.409 | 22.411 |
Other Long Term Assets, Total | 6.024 | 6.425 | 6.744 | 6.919 | 7.012 |
Total Current Liabilities | 209.415 | 194.072 | 254.746 | 273.562 | 251.994 |
Accounts Payable | 19.22 | 12.802 | 71.282 | 30.758 | 19.323 |
Accrued Expenses | 182.87 | 173.78 | 166.969 | 229.639 | 224.577 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0.036 | ||||
Other Current Liabilities, Total | 7.325 | 7.49 | 16.495 | 13.129 | 8.094 |
Total Liabilities | 617.595 | 617.401 | 587.396 | 631.534 | 582.531 |
Total Long Term Debt | 88.608 | 88.773 | 17.276 | 17.054 | 15.422 |
Long Term Debt | 88.608 | 88.773 | 17.276 | 16.917 | 15.422 |
Capital Lease Obligations | 0.137 | ||||
Deferred Income Tax | |||||
Minority Interest | 41.967 | 41.967 | 19.967 | 19.967 | 19.967 |
Other Liabilities, Total | 277.605 | 292.589 | 295.407 | 320.951 | 295.148 |
Total Equity | -157.169 | -102.274 | -48.852 | -21.447 | 26.306 |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | |
Common Stock | 0.983 | 0.982 | 0.966 | 0.942 | 0.939 |
Additional Paid-In Capital | 1634.46 | 1625.07 | 1589.15 | 1541.02 | 1524.23 |
Retained Earnings (Accumulated Deficit) | -1785.69 | -1722.07 | -1634.39 | -1557.69 | -1491.51 |
Other Equity, Total | -6.923 | -6.25 | -4.57 | -5.72 | -7.346 |
Total Liabilities & Shareholders’ Equity | 460.426 | 515.127 | 538.544 | 610.087 | 608.837 |
Total Common Shares Outstanding | 98.3391 | 98.2042 | 96.623 | 94.1661 | 93.936 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -293.654 | -290.023 | -189.291 | -76.97 | -86.42 |
Cash From Operating Activities | -145.933 | -82.232 | 81.602 | -78.705 | -76.144 |
Cash From Operating Activities | 10.604 | 14.809 | 22.047 | 21.454 | 6.562 |
Non-Cash Items | 66.687 | 132.899 | 74.216 | 62.47 | 52.112 |
Cash Interest Paid | 0.104 | 0.094 | 0.135 | 0.174 | 0.218 |
Changes in Working Capital | 70.43 | 60.083 | 174.63 | -85.659 | -48.398 |
Cash From Investing Activities | 89.116 | -426.972 | 452.487 | 120.018 | -522.123 |
Capital Expenditures | -38.741 | -30.186 | -3.994 | -5.762 | -8.02 |
Other Investing Cash Flow Items, Total | 127.857 | -396.786 | 456.481 | 125.78 | -514.103 |
Cash From Financing Activities | 46.776 | -0.563 | 13.343 | -4.3 | 13.875 |
Financing Cash Flow Items | -6.62 | -7.372 | -11.463 | -12.75 | -15.612 |
Issuance (Retirement) of Stock, Net | 53.934 | 12.701 | 37.829 | 20.778 | 29.847 |
Issuance (Retirement) of Debt, Net | -0.538 | -5.892 | -13.023 | -12.328 | -0.36 |
Foreign Exchange Effects | -5.482 | 2.597 | 4.695 | -0.005 | -0.008 |
Net Change in Cash | -15.523 | -507.17 | 552.127 | 37.008 | -584.4 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -76.705 | -293.654 | -227.479 | -135.829 | -63.205 |
Cash From Operating Activities | -101.591 | -145.933 | -93.42 | -41.54 | -8.476 |
Cash From Operating Activities | 2.965 | 10.604 | 7.914 | 5.235 | 2.584 |
Non-Cash Items | 18.148 | 66.687 | 49.928 | 34.441 | 17.77 |
Changes in Working Capital | -45.999 | 70.43 | 76.217 | 54.613 | 34.375 |
Cash From Investing Activities | 103.482 | 89.116 | 88.023 | 43.24 | 25.935 |
Capital Expenditures | -0.591 | -38.741 | -38.408 | -37.543 | -36.638 |
Other Investing Cash Flow Items, Total | 104.073 | 127.857 | 126.431 | 80.783 | 62.573 |
Cash From Financing Activities | 31.485 | 46.776 | -1.898 | -0.806 | -2.893 |
Financing Cash Flow Items | 0 | -6.62 | -4.562 | -3.361 | -2.974 |
Issuance (Retirement) of Stock, Net | 31.657 | 53.934 | 2.989 | 2.779 | 0.183 |
Issuance (Retirement) of Debt, Net | -0.172 | -0.538 | -0.325 | -0.224 | -0.102 |
Foreign Exchange Effects | -0.526 | -5.482 | -7.968 | -4.359 | 0.107 |
Net Change in Cash | 32.85 | -15.523 | -15.263 | -3.465 | 14.673 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
FibroGen, Inc Company profile
About FibroGen Inc
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing a pipeline of first-in-class therapeutics. The Company applies its capabilities in hypoxia-inducible factor (HIF) biology, 2-oxoglutarate enzymology, and connective tissue growth factor (CTGF) biology to advance medicines for the treatment of anemia, fibrotic disease, and cancer. The Company’s product Roxadustat is an oral small molecule inhibitor of HIF-prolyl hydroxylase (HIF-PH) activity for the treatment of anemia caused by chronic kidney disease (CKD). It is also developing Roxadustat for anemia associated with myelodysplastic syndromes (MDS). The Company is also developing Roxadustat for the treatment of chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), and Duchenne muscular dystrophy (DMD).
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, FibroGen Inc revenues increased 33% to $235.3M. Net loss increased 53% to $290M. Revenues reflect Europe segment increase of 95% to $131.2M. Higher net loss reflects Research and Development -Balancing increase of 68% to $346.5M (expense), General and Administrative -Balancing increase of 27% to $89.9M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$2.11 to -$3.14.
Industry: | Biotechnology & Medical Research (NEC) |
409 Illinois Street
SAN FRANCISCO
CALIFORNIA 94158
US
Income Statement
- Annual
- Quarterly
News
A way forward: a roundup of recent central bank decisions
Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.
12:47, 22 March 2024Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024Higher CPI leaves traders unfazed as US equities continue to build momentum
The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.
12:42, 15 March 2024Four reasons why Bitcoin is surging to record highs
Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.
10:18, 14 March 2024China’s National People’s Congress: The markets have again been left wanting more
China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.
08:23, 8 March 2024Central Banks: which one will cut first?
Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut
13:14, 6 March 2024Nvidia (NVDA) confronts high expectations for Q4 results
Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.
12:13, 20 February 2024People also watch
Still looking for a broker you can trust?
Join the 580.000+ traders worldwide that chose to trade with Capital.com